Scandinavian ChemoTech thanks for the cooperation with its IR consultant who leaves the management team

After more than a year of collaboration, the company and the IR consultant, Jonathan Furelid, have mutually decided to end the collaboration as a result of changing needs for the company regarding its communication. Jonathan thus leaves the management team as of December 31.

ChemoTech has initiated the recruitment of a marketing and communications manager to develop the work of increasing the awareness of the Company's unique cancer technology, TSE (Tumor Specific Electroporation) in both Human and Animal Care.

"We thank Jonathan for his efforts and wish him continued success in his work", says Mohan Frick, CEO of Scandinavian ChemoTech.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: [email protected]

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.